(PRWEB) August 27, 2014
Pressure BioSciences Inc., ("PBI") (OTCQB: PBIO), Exclusive Interview for Interlinked's Investment News Channel, InterlinkedTV at FSXinterlinked Investment Conference.
Pressure BioSciences Inc., ("PBI") (OTCQB: PBIO), a company focused on the development, marketing, and sale of proprietary laboratory instrumentation and associated consumables based on Pressure Cycling Technology (“PCT”), granted Interlinked an exclusive interview at the recent FSXinterlinked Investment Conference, held at Westlake Village, California.
Pressure BioSciences Inc., ("PBI") (OTCQB: PBIO) was one of the presenting companies at the recent FSXinterlinked Investment Conference, held at the Four Seasons Hotel in Westlake Village, California.
PBI is focused on the development, marketing, and sale of proprietary laboratory instrumentation and associated consumables based on Pressure Cycling Technology (“PCT”). PCT is a patented, enabling technology platform with multiple applications in the estimated $6 billion life sciences sample preparation market. PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions for the subsequent, high-quality analysis of samples in scientific studies.
During the event, FSXinterlinked host, Michael Fugler, interviewed Mr. Richard T. Schumacher, PBI President and CEO.
"Michael possesses extraordinary interviewing skills, which enable him to ask just the right questions to get the simplest, most informative descriptions of what these companies do and who these entrepreneurs are,” stated Mr. Delray Wannemacher, FSXinterlinked President.
During the interview, Mr. Schumacher discussed PBI and its powerful and enabling PCT platform and shared exciting news about the company.
Mr. Schumacher stated, "We are a life sciences tools company. We design, manufacture, market, and sell PCT-based instruments and corresponding consumables to the life science research market. We believe our target market includes about 500,000 researchers in over 80,000 laboratories worldwide. That's a very big market."
Mr. Schumacher continued, "We have 24 issued patents, over 100 independent scientific publications on our website discussing the advantages of PCT, over 150 existing customers, and over 250 instrument systems installed. Our instruments contain a computer-controlled pressure chamber. Scientists place cells to be analyzed in disposable test tubes inside the pressure chamber, tell the computer how much pressure to exert, how long to exert it, and how many times to turn the pressure on and off (thus, pressure cycling). Our instruments can safely and carefully generate pressures between 5,000 and 100,000 PSI. Since everything in nature has a pressure point, once that pressure point has been determined, the scientist is able to reproducibly and effectively place the exact amount of pressure needed to control the cell (bust it open, extract out the DNA, etc.) on each and every experiment.
There are many thousands of scientists worldwide who spend their lives looking for disease markers (“biomarkers”), in an effort to prevent, detect, control, eradicate, or cure the disease. This nearly always requires breaking open the cell and releasing the DNA, RNA, proteins, and lipids that make it up. Current methods to break cells usually rely on mechanical means (tiny beads for puncture, miniature blades to chop, etc.) and are, we believe, woefully inadequate. The PCT platform uses very gentle but powerful pulses of various levels of pressure, which our customers have found to be more reproducible and controllable than mechanical methods.
Mr. Schumacher concluded: “We have announced the release of two new instruments and two additional consumable processing tubes during the first six months of 2014. We have also announced that product sales during the half of 2014 have increased 70% over the same period in 2013, and we have not yet begun to sell the two new instrument systems. We believe, therefore, that we have many reasons to be very excited about the second half of 2014, and beyond.”
The complete exclusive interview is available only on the FSXinterlinked channel on InterlinkedTV.
More information is available at PBI's Public Profile on Interlinked.com and on their website.
About FSXinterlinked Investment Conference
FSXinterlinked is the premier investment conference organization in the United States. Founded as Financial Services Exchange (FSX) in 1983, it is one of the longest standing and most trusted investment conferences in the country for Broker Dealers and financial professionals. For more information about our organization please visit FSXinterlinked.com
Interlinked is a global investment community of investors, emerging growth companies, and resource partners. Interlinked offers an efficient way for companies to maximize exposure and access a private network of funding sources and verified service providers. For investors, Interlinked provides a secure environment to find, vet and engage companies, and communicate with members. Interlinked gives members exclusive access to a proprietary investment platform, which integrates virtual data rooms, video news, a service provider marketplace, an event directory, and customized marketing services, including email marketing, video production, public relations and more. For more information, visit: http://www.interlinked.com/.
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (“PBI”) (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary development and sales efforts are in the biomarker discovery, drug discovery and design, and forensics areas. Customers also use our products in other areas, such as bio-therapeutics characterization, soil & plant biology, vaccine development, and counter-bioterror applications.
Safe Harbor Statement
This press release may contain information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release, including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.